How Does Sinocare Company Work?

Sinocare's product portfolio includes household and medical blood glucose meters, such as the Safe-Accu and Gold AQ Plus series, alongside blood glucose test strips and urinary microalbumin test strips. The company also offers blood lipid uric acid products and HbA1c testing systems.

The company is at the forefront of continuous glucose monitoring (CGM) technology, with offerings like the Sinocare iCan CGM 2nd Generation. This demonstrates their commitment to providing comprehensive diabetes management tools.

Sinocare's operations are underpinned by significant investment in research and development, with approximately 8.1% of its total revenue, or ¥200 million, allocated to R&D in 2023. This investment fuels technological advancements, such as its third-generation direct electronic transfer technology for CGM.

With manufacturing facilities like the Sinocare Lu Valley Biosensor Manufacturing Facility, the company achieves economies of scale, contributing to a gross margin of 50% in 2022. Sinocare holds an estimated 30% share in the Chinese diabetes care market as of 2023.

Founded in 2002, Sinocare quickly became a leader in China's blood glucose monitoring market. A major strategic move was its international expansion through significant acquisitions, including PTS Diagnostics Inc. in 2016 for $200 million and Nipro Diagnostics Inc. (now Trividia Health Inc.) for $273 million. These acquisitions propelled the company to become the world's fifth largest blood glucose meter manufacturer, broadening its product offerings and global reach.

Recent years have seen a strong focus on Continuous Glucose Monitoring (CGM) technology. The Sinocare iCan CGM 2nd Generation achieved CE-MDR certification in July 2025, a critical step for EU market access. This was further bolstered by a strategic partnership with A. Menarini Diagnostics in December 2024, securing exclusive distribution rights for its 3rd Generation CGM system across over 20 European countries, targeting reimbursed markets.

The company has navigated operational hurdles and market competition, including intellectual property disputes. A notable instance was prevailing in a trademark dispute with Abbott in the UK courts in February 2025. Additionally, a lawsuit was filed by Roche in June 2024 concerning diabetes test-strip patents. Sinocare addresses these challenges through ongoing innovation and strong legal defense.

Sinocare's competitive edge is built on its strong brand recognition, particularly in China, which allows for economies of scale. Its technological leadership in biosensing, exemplified by the accuracy of its Gold AQ Glucose Monitoring System, provides a distinct advantage. The company's commitment to research and development, with approximately 8.1% of revenue invested in 2023, fuels continuous product innovation and adaptation to digital health trends.

Sinocare is a dominant force in the diabetes management industry, particularly in Asia. Its competitive edge is built on providing accessible and reliable blood glucose monitoring solutions, making it a key provider in the Target Market of Sinocare.

The company competes with established global players such as Johnson & Johnson Services Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Medtronic plc. Other significant competitors in the glucometer market include Yuwell and DexCom Inc.

The company's future strategy focuses on global expansion, exemplified by its Indonesian subsidiary, and continuous innovation in CGM systems and AI-driven diabetes management. Sinocare aims to enhance its role as a leading diabetes digital management expert through efficient and user-friendly solutions.